AstraZeneca"s forecasts boosted by Crestor sales and withdrawal of generics
스크롤 이동 상태바
AstraZeneca"s forecasts boosted by Crestor sales and withdrawal of generics
기자명
메디칼라이터팀
입력 2009.08.03 00:00
수정 2009.08.03 07:57
댓글 0
Increasing sales of cholesterol drug Crestor [rosuvastatin calcium], along with the delayed introduction in the US of a generic competitor for the cancer drug Casodex [bicalutamide], and the withdrawal in the US of two generic competitors to Toprol-XL [metoprolol succinate], a blood pressure drug have boosted AstraZeneca"s predicted earnings for the financial year. The company"s CEO, David Brennan said that the global economy has not affected the company"s business as much as expected and that the company"s four new approval filings are on schedule including the new diabetes drug Onglyza [saxagliptin] which is being developed with Bristol-Myers Squibb. Its nasal spray swine flu vaccine has a $90 million order by US Department of Health and Human Services. The initial order will be used for those at risk in the case of a pandemic.